Clinical trials: sponsored by Boehringer Ingelheim
Hepatitis C, Chronic
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
This study will investigate safety, antiviral activity, and pharmacokinetics of BI 201335 NA in HCV genotype 1 infected patients treated for 14 days monotherapy followed by BI 201335 NA combination therapy with PegIFN/RBV for an…
- Trial name
- NCT00793793
- Testing
- BI201335
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Follicular
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
The primary objective of the study is to assess the pharmacokinetic (PK) similarity of Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients with low tumor burden follicular lymphoma (LTBFL).
- Trial name
- NCT01950273
- Testing
- BI 695500, MabThera
- Where
- 29 sites in Australia, Austria and 11 more
- Volunteers
- 95 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI
- Trial name
- NCT02172404
- Testing
- Ipratropium metered dose inhaler (MDI)
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers
First evaluation of safety, tolerability, pharmacokinetics and the pharmacodynamic effect of BI 11634 on coagulation parameters
- Trial name
- NCT02214914
- Testing
- BI 11634 drinking solution, BI 11634 tablet
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
- Trial name
- NCT02172495
- Testing
- Tiotropium bromide
- Volunteers
- 4,700 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.
The objective of the current study is to demonstrate bioequivalence of a fixed dose combination tablet containing ibuprofen 200 mg and pseudoephedrine-HCl 30 mg (Test) and RhinAdvil® (Reference) a fixed dose combination tablet…
- Trial name
- NCT01170637
- Testing
- Ibuprofen, Pseudoephedrine-HCl
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dysmenorrhea
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic…
- Trial name
- NCT02183025
- Testing
- Meloxicam 7.5 mg, Meloxicam 15 mg, Mefenamic acid 500 mg
- Volunteers
- 337 people
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin
To investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single rising doses from 50 mg to 350 mg in healthy male subjects of Japanese and Caucasian origin.
- Trial name
- NCT02170844
- Testing
- BIBR 1048 MS
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with…
- Trial name
- NCT02182869
- Testing
- Combivent® HFA inhalation aerosol, Combivent® CFC inhalation aerosol
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers
Pharmacokinetics (relative bioavailability), safety and tolerability
- Trial name
- NCT02182960
- Testing
- Ibuprofen syrup, Brufen syrup
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of multiple increasing doses of BIIX 1 XX and to obtain preliminary pharmacokinetic data
- Trial name
- NCT02198313
- Testing
- BIIX 1 XX - D1, BIIX 1 XX - D2, BIIX 1 XX - D3
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers
To investigate the bioavailability of dabigatran with and without concomitant administration of atorvastatin and the bioavailability of atorvastatin with and without concomitant administration of dabigatran etexilate
- Trial name
- NCT02171039
- Testing
- Dabigatran, Atorvastatin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC)…
- Trial name
- NCT02182674
- Testing
- Combivent HFA, Combivent (CFC)
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d.
- Trial name
- NCT02170909
- Testing
- BIBR 1048 MS low dose, BIBR 1048 MS medium dose, BIBR 1048 MS high dose
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery
To determine the therapeutic window of BIBR 1048 in order to select doses for further studies in the development plan. Twice daily regimen will be tested for most dose levels and once daily administration will also be evaluated…
- Trial name
- NCT02170701
- Testing
- BIBR 1048
- Volunteers
- 289 people
- Sponsor
- Boehringer Ingelheim
Healthy
Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers
The primary objective of the current study is to investigate the safety and tolerability of BI 1181181 in healthy young male and elderly male and female volunteers following oral administration of repeated rising doses of BI…
- Trial name
- NCT02254161
- Testing
- BI 1181181 healthy elderly, BI 1181181 Healthy young
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation in patients with COPD using oxitropium bromide (Tersigan) as a comparator.
- Trial name
- NCT02172430
- Testing
- Tiotropium powder inhalation capsules, Tersigan®
- Volunteers
- 161 people
- Sponsor
- Boehringer Ingelheim
Healthy
Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects
1. To investigate the relative bioavailability (BA) of improved tablet formulation candidates to determine which formulation will be developed for use in late Phase II and Phase III clinical trials 2.
- Trial name
- NCT02259868
- Testing
- BILR 355 BS /1B, current low dose formulation, BILR 355 BS /1B, current high dose formulation, BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)
To describe the plasma and urinary pharmacokinetics of quercetin glucuronide and kaempferol glucuronide after the administration of a single peroral dose of 1,800mg Red Vine Leaf Extract (Antistax®).
- Trial name
- NCT02191241
- Testing
- Red Vine Leaf Extract
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to evaluate the effect of tiotropium on gross muscular efficiency
- Trial name
- NCT02172794
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.